Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Diabetes Obes Metab. 2008 Sep; 10(10):959-69.DO

Abstract

AIM

To assess the addition of sitagliptin to ongoing metformin therapy in patients with type 2 diabetes who were inadequately controlled [haemoglobin A(1c) (HbA(1c)) 7-11%] on metformin monotherapy.

METHODS

Patients (n = 273) on metformin (>/=1500 mg/day) were randomized to receive the addition of once-daily placebo, sitagliptin 100 mg or rosiglitazone 8 mg in a 1 : 1 : 1 ratio for 18 weeks. The efficacy analysis was based on the all-patients-treated population using an analysis of co-variance with change in HbA(1c) from baseline as the primary endpoint.

RESULTS

The mean baseline HbA(1c) was 7.7% for the entire cohort. After 18 weeks, both active add-on therapies led to greater improvements in HbA(1c) from baseline: -0.73% for sitagliptin (p < 0.001 vs. placebo) and -0.79% for rosiglitazone compared with -0.22% for placebo. No difference was observed between the sitagliptin and rosiglitazone treatments (0.06% [95% confidence interval (CI): -0.14 to 0.25]). The proportion of patients achieving an HbA(1c) < 7% was greater with sitagliptin (55%) and rosiglitazone (63%) compared with placebo (38%). Body weight increased from baseline with rosiglitazone (1.5 kg) compared with body weight reduction with sitagliptin (-0.4 kg) and placebo (-0.8 kg). The difference in body weight between the sitagliptin and rosiglitazone groups was 1.9 kg (95% CI: 1.3-2.5). In a prespecified analysis, the proportion of patients experiencing a greater than 3-kg increase in body weight was 21% in the rosiglitazone group compared with 2% in both the sitagliptin and placebo groups. Both active treatments were generally well tolerated, with no increased risk of hypoglycaemia or gastrointestinal adverse events compared with placebo.

CONCLUSIONS

In this 18-week study, the addition of sitagliptin was effective and well tolerated in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Treatment with sitagliptin produced similar reductions in HbA(1c) compared with the addition of rosiglitazone.

Authors+Show Affiliations

Lipid and Diabetes Research Group, Christchurch School of Medicine, Christchurch, New Zealand.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18201203

Citation

Scott, R, et al. "Efficacy and Safety of Sitagliptin when Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes." Diabetes, Obesity & Metabolism, vol. 10, no. 10, 2008, pp. 959-69.
Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959-69.
Scott, R., Loeys, T., Davies, M. J., & Engel, S. S. (2008). Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 10(10), 959-69. https://doi.org/10.1111/j.1463-1326.2007.00839.x
Scott R, et al. Efficacy and Safety of Sitagliptin when Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes. Diabetes Obes Metab. 2008;10(10):959-69. PubMed PMID: 18201203.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. AU - Scott,R, AU - Loeys,T, AU - Davies,M J, AU - Engel,S S, AU - ,, Y1 - 2008/01/14/ PY - 2008/1/19/pubmed PY - 2009/5/5/medline PY - 2008/1/19/entrez SP - 959 EP - 69 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 10 IS - 10 N2 - AIM: To assess the addition of sitagliptin to ongoing metformin therapy in patients with type 2 diabetes who were inadequately controlled [haemoglobin A(1c) (HbA(1c)) 7-11%] on metformin monotherapy. METHODS: Patients (n = 273) on metformin (>/=1500 mg/day) were randomized to receive the addition of once-daily placebo, sitagliptin 100 mg or rosiglitazone 8 mg in a 1 : 1 : 1 ratio for 18 weeks. The efficacy analysis was based on the all-patients-treated population using an analysis of co-variance with change in HbA(1c) from baseline as the primary endpoint. RESULTS: The mean baseline HbA(1c) was 7.7% for the entire cohort. After 18 weeks, both active add-on therapies led to greater improvements in HbA(1c) from baseline: -0.73% for sitagliptin (p < 0.001 vs. placebo) and -0.79% for rosiglitazone compared with -0.22% for placebo. No difference was observed between the sitagliptin and rosiglitazone treatments (0.06% [95% confidence interval (CI): -0.14 to 0.25]). The proportion of patients achieving an HbA(1c) < 7% was greater with sitagliptin (55%) and rosiglitazone (63%) compared with placebo (38%). Body weight increased from baseline with rosiglitazone (1.5 kg) compared with body weight reduction with sitagliptin (-0.4 kg) and placebo (-0.8 kg). The difference in body weight between the sitagliptin and rosiglitazone groups was 1.9 kg (95% CI: 1.3-2.5). In a prespecified analysis, the proportion of patients experiencing a greater than 3-kg increase in body weight was 21% in the rosiglitazone group compared with 2% in both the sitagliptin and placebo groups. Both active treatments were generally well tolerated, with no increased risk of hypoglycaemia or gastrointestinal adverse events compared with placebo. CONCLUSIONS: In this 18-week study, the addition of sitagliptin was effective and well tolerated in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Treatment with sitagliptin produced similar reductions in HbA(1c) compared with the addition of rosiglitazone. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/18201203/Efficacy_and_safety_of_sitagliptin_when_added_to_ongoing_metformin_therapy_in_patients_with_type_2_diabetes_ L2 - https://doi.org/10.1111/j.1463-1326.2007.00839.x DB - PRIME DP - Unbound Medicine ER -